S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:MRKR - TapImmune Stock Price, Forecast & News

$2.66
-0.08 (-2.92 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$2.61
Now: $2.66
$2.75
50-Day Range
$2.59
MA: $2.88
$3.35
52-Week Range
$2.45
Now: $2.66
$9.17
Volume241,044 shs
Average Volume284,626 shs
Market Capitalization$121.62 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.21
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRKR
CUSIPN/A
CIKN/A
Phone713-400-6400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210,000.00
Book Value$1.31 per share

Profitability

Net Income$-147,960,000.00

Miscellaneous

Employees11
Market Cap$121.62 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive MRKR News and Ratings via Email

Sign-up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.


TapImmune (NASDAQ:MRKR) Frequently Asked Questions

What is TapImmune's stock symbol?

TapImmune trades on the NASDAQ under the ticker symbol "MRKR."

How were TapImmune's earnings last quarter?

TapImmune Inc. (NASDAQ:MRKR) posted its earnings results on Tuesday, November, 12th. The company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. View TapImmune's Earnings History.

When is TapImmune's next earnings date?

TapImmune is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for TapImmune.

What price target have analysts set for MRKR?

7 equities research analysts have issued 1-year target prices for TapImmune's shares. Their forecasts range from $5.00 to $16.00. On average, they anticipate TapImmune's stock price to reach $9.90 in the next year. This suggests a possible upside of 272.1% from the stock's current price. View Analyst Price Targets for TapImmune.

What is the consensus analysts' recommendation for TapImmune?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TapImmune in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TapImmune.

What are Wall Street analysts saying about TapImmune stock?

Here are some recent quotes from research analysts about TapImmune stock:
  • 1. According to Zacks Investment Research, "Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States. " (2/15/2020)
  • 2. Nomura analysts commented, "Ph2 AML IND in 3Q19, Data update Pivotal (Accelerated Approval?). The trial will evaluate multiTAAs in post-aHSCT patients in both active and adjuvant settings. We believe post-transplant AML is a logical approach to rapid registration, given promising data to date and potential for accelerated approval. We see three key AML settings with registration potential: r/r post-transplant; MRD(-) post-transplant (taking advantage of the recent FDA guidance document. See also our initiation for more on MulitTAA potential in AML. Our View. MRKR presented data from the TACTOPS trial (NCT03192462, IST) testing MultiTAA in pancreatic cancer (see our note). We were encouraged by the results, noting the difficulty of pancreatic cancer as a solid tumor with low immunogenicity and fibrotic microenvironment." (8/13/2019)

Has TapImmune been receiving favorable news coverage?

Press coverage about MRKR stock has trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TapImmune earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for TapImmune.

Who are some of TapImmune's key competitors?

What other stocks do shareholders of TapImmune own?

Who are TapImmune's key executives?

TapImmune's management team includes the folowing people:
  • Mr. Peter L. Hoang MBA, Pres, CEO & Director (Age 47)
  • Mr. Anthony H. Kim, Chief Financial Officer (Age 43)
  • Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec. (Age 53)
  • Dr. Ann M. Leen, Chief Scientific Officer
  • Ms. Elizabeth Donnelly, Director of Admin.

Who are TapImmune's major shareholders?

TapImmune's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Riggs Asset Managment Co. Inc. (0.08%). View Institutional Ownership Trends for TapImmune.

Which major investors are selling TapImmune stock?

MRKR stock was sold by a variety of institutional investors in the last quarter, including Riggs Asset Managment Co. Inc.. View Insider Buying and Selling for TapImmune.

How do I buy shares of TapImmune?

Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TapImmune's stock price today?

One share of MRKR stock can currently be purchased for approximately $2.66.

How big of a company is TapImmune?

TapImmune has a market capitalization of $121.62 million and generates $210,000.00 in revenue each year. The company earns $-147,960,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. TapImmune employs 11 workers across the globe.View Additional Information About TapImmune.

What is TapImmune's official website?

The official website for TapImmune is http://www.markertherapeutics.com/.

How can I contact TapImmune?

TapImmune's mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at 713-400-6400 or via email at [email protected]


MarketBeat Community Rating for TapImmune (NASDAQ MRKR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  95
MarketBeat's community ratings are surveys of what our community members think about TapImmune and other stocks. Vote "Outperform" if you believe MRKR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRKR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Why do commodities matter?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel